To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Immunotherapy with HDC/IL… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Journal article
Authors Malin S. Nilsson
Alexander Hallner
Mats Brune
Staffan Nilsson
Fredrik Bergh Thorén
Anna Martner
Kristoffer Hellstrand
Published in Human Vaccines & Immunotherapeutics
ISSN 2164-5515
Publication year 2019
Published at Department of Mathematical Sciences
Sahlgrenska Cancer Center
Institute of Medicine
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Institute of Biomedicine, Department of Infectious Medicine
Language en
Keywords Acute myeloid leukemia, histamine dihydrochloride, IL-2, immunotherapy, relapse prevention, mutations, aml, Biotechnology & Applied Microbiology, Immunology
Subject categories Immunology in the medical area, Hematology, Cancer and Oncology


Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?